IP Library Granted Patent US 8,637,291
Granted Patent B2
US 8,637,291 · App. 13/022,561 · Granted Jan 28, 2014

High fidelity restriction endonucleases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,291
App. No.
13/022,561
Granted
Jan 28, 2014
Kind
B2
Abstract

Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer.

Claims (12)

1. A composition comprising a variant PvuI restriction endonuclease having reduced star activity wherein the variant PvuI polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent PvuI polypeptide by a mutation at an amino acid position corresponding to position 36 of SEQ ID NO:1.

2. The composition of claim 1 , wherein the mutation is S36A.

3. A composition comprising a variant PvuI restriction endonuclease having reduced star activity wherein the variant PvuI polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent PvuI polypeptide by a mutation at an amino acid position corresponding to position 77 of SEQ ID NO:1.

4. The composition of claim 3 , wherein the mutation is K77A.

5. A composition comprising a variant PvuI restriction endonuclease having reduced star activity wherein the variant PvuI polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent PvuI polypeptide by a mutation at an amino acid position corresponding to position 154 of SEQ ID NO:1.

6. The composition of claim 5 , wherein the mutation is P154A.

7. A composition comprising a variant PvuI restriction endonuclease having reduced star activity wherein the variant PvuI polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent PvuI polypeptide by a mutation at an amino acid position corresponding to position 163 of SEQ ID NO:1.

8. The composition of claim 7 , wherein the mutation is E163A.

9. A composition comprising a variant PvuI restriction endonuclease having reduced star activity wherein the variant PvuI polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent PvuI polypeptide by a mutation at an amino acid position corresponding to position 165 of SEQ ID NO:1.

10. The composition of claim 9 , wherein the mutation is Y165F.

11. A composition comprising a variant PvuI restriction endonuclease having reduced star activity wherein the variant PvuI polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent PvuI polypeptide by a mutation at an amino acid position corresponding to position 185 of SEQ ID NO:1.

12. The composition of claim 11 , wherein the mutation is K185A.

Assignments (3)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2015
From: ZHU, ZHENYU; QUIMBY, AINE; GUAN, SHENGXI; SUN, DAPENG; HUANG, YISHU; LAI, XUHUI; CHAN, SIU-HONG; LI, XIANGHUI; XU, SHUANG-YONG; ZHANG, CHUNHUA
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 035068/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2011
From: ZHU, ZHENYU; QUIMBY, AINE; GUAN, SHENGXI; SUN, DAPENG; HUANG, YISHU; LAI, XUHUI; CHAN, SIU-HONG; LI, XIANGHUI; XU, SHUANG-YONG; ZHANG, CHUNHUA
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 025887/0672 →